Study #2018-1160
A Phase I, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, Cc-99282, Alone And In Combination With Anti-Lymphoma Agent In Subjects With Relapsed Or Refractory Non-Hodgk
MD Anderson Study Status
Enrolling
Treatment Agent
CC-99282, rituximab
Description
CC-99282-NHL-001 study is a Phase I dose escalation and expansion clinical study of CC-99282 administered alone and in combination with rituximab in subjects with relapsed or refractory non-hodgkin Lymphomas (R/R NHL).
Information and next steps
Disease:
Lymphoma, Non-Hodgkin
Study phase:
I
Physician name:
Loretta Nastoupil
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.